CapsoVisionCV +7.58%10 EBIT per Share is $-0.58 as of Mar. 2026. GuruFocus rates CV with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 691 Medical Devices & Instruments companies, CapsoVision ranks worse than 144717.66% on this metric.
CapsoVision's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.15.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.58.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for CapsoVision's EBIT per Share or its related term are showing as below:
CV's 3-Year EBIT Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 9.6 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
CapsoVision's EBIT for the
three
months ended in Mar. 2026 was $-7.09 Mil.
CapsoVision (NAS:CV) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
CapsoVision EBIT per Share Related Terms
CapsoVision EBIT per Share Historical Data
* Premium members only.
The historical data trend for CapsoVision's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.58
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CapsoVision (CV) has a EBIT per Share of $-0.58 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CapsoVision and its competitors. According to the industry distribution chart, CapsoVision ranks #999999 out of 691 companies in the Medical Devices & Instruments industry.
Is CapsoVision's EBIT per Share too high?
CapsoVision's current EBIT per Share is $-0.58. Based on the distribution chart, CapsoVision ranks #999999 out of 691 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, CapsoVision has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does CapsoVision's EBIT per Share compare to OFIX and CATX?
According to the Medical Devices & Instruments industry distribution chart, CapsoVision ranks #999999 out of 691 companies for EBIT per Share. This places CapsoVision in the lower half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CapsoVision and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CapsoVision's current EBIT per Share is $-0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CapsoVision stock overvalued right now?
CapsoVision (CV) has a current EBIT per Share of $-0.58. The current EBIT per Share is $-0.58. CapsoVision's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For CapsoVision (CV), the current EBIT per Share is $-0.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CapsoVision Inc is a commercial-stage medical technology enterprise that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. The company's core technology platform is an orally ingestible capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. CapsoVision's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D, directed at the large intestines. Geographically, the company generates the majority of its revenue from the United States.
10GF Score
Get the complete analysis for CV
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CV has been successfully added to your 
